{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:52:15Z","timestamp":1793760735866,"version":"4.6.1"},"reference-count":39,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,30]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Epcoritamab and glofitamab are CD20-directed bispecific antibodies (BsAbs) approved in the United States for relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL). Limited data exist for patients treated outside of trials. Patients with R\/R DLBCL receiving commercial epcoritamab or glofitamab between 1 January 2023 and 15 October 2024 were collected from 21 United States institutions. Among 245 patients, 156 received epcoritamab and 89 received glofitamab, 113 were refractory to front-line therapy, 40 had MYC and BCL2 and\/or BCL6 rearrangements, 147 received prior chimeric antigen receptor T-cell therapy, and 174 patients would have been ineligible for registrational trials. The overall response rate (ORR) for epcoritamab and glofitamab was 51% (23% complete response, [CR]) and 53% (30% CR), respectively. Median progression-free survival (PFS) was 2.6 months (95% confidence interval [CI], 2.0-3.8 months), and median overall survival (OS) was 7.8 months (95% CI, 6.2-11.0 months). The 6-month PFS was 36% (95% CI, 30-44) and the 6-month OS was 60% (95% CI, 54-67). Both trial ineligibility and undetectable CD20 pre-BsAbs portended shorter PFS and OS. Of 17 individuals with paired biopsies, 15 (88.2%) lost CD20 expression after BsAbs with a median time to progression of 3.7 months. This analysis including patients with R\/R DLBCL shows the ORR to CD3\/CD20 BsAbs was comparable to pivotal trials, although PFS and OS were lower. Baseline undetectable levels of CD20 were associated with poor outcomes. These results demonstrate the activity of BsAbs in R\/R DLBCL, and underscore the importance of target antigen expression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025029117","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:57:43Z","timestamp":1752613063000},"page":"2177-2188","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":47,"title":["Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4352-9296","authenticated-orcid":false,"given":"Taylor R.","family":"Brooks","sequence":"first","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1402-4498","authenticated-orcid":false,"given":"Emily C.","family":"Zabor","sequence":"additional","affiliation":[{"name":"2Department of Quantitative Health Sciences, Cleveland Clinic Research, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohanna B.","family":"Bedelu","sequence":"additional","affiliation":[{"name":"2Department of Quantitative Health Sciences, Cleveland Clinic Research, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2648-4448","authenticated-orcid":false,"given":"Yasmin H.","family":"Karimi","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne N.","family":"Nedved","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Dave","sequence":"additional","affiliation":[{"name":"5Division of Hematology-Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Landsburg","sequence":"additional","affiliation":[{"name":"5Division of Hematology-Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8115-7322","authenticated-orcid":false,"given":"Kelsey","family":"Baron","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Hematologic Malignancies, University of Utah Huntsman Cancer Institute, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyu","family":"Hu","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Hematologic Malignancies, University of Utah Huntsman Cancer Institute, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3997-5286","authenticated-orcid":false,"given":"Daniel C.","family":"Trotier","sequence":"additional","affiliation":[{"name":"7Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin Carbone Cancer Center, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2410-9540","authenticated-orcid":false,"given":"Priyanka A.","family":"Pophali","sequence":"additional","affiliation":[{"name":"7Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin Carbone Cancer Center, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Miller","sequence":"additional","affiliation":[{"name":"8Division of Hematology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-3157","authenticated-orcid":false,"given":"Natalie","family":"Grover","sequence":"additional","affiliation":[{"name":"8Division of Hematology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Reinert","sequence":"additional","affiliation":[{"name":"9Division of Hematology, University of Colorado Cancer Center, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7261-1335","authenticated-orcid":false,"given":"Ajay","family":"Major","sequence":"additional","affiliation":[{"name":"9Division of Hematology, University of Colorado Cancer Center, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenley","family":"Schwarz","sequence":"additional","affiliation":[{"name":"10Swedish Cancer Institute, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krish","family":"Patel","sequence":"additional","affiliation":[{"name":"10Swedish Cancer Institute, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5311-0815","authenticated-orcid":false,"given":"Kiarash","family":"Salafian","sequence":"additional","affiliation":[{"name":"11Division of Hematology and Oncology, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3748-4507","authenticated-orcid":false,"given":"Emily","family":"Ayers","sequence":"additional","affiliation":[{"name":"11Division of Hematology and Oncology, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchitra","family":"Sundaram","sequence":"additional","affiliation":[{"name":"12Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0850-6730","authenticated-orcid":false,"given":"Joshua D.","family":"Brody","sequence":"additional","affiliation":[{"name":"12Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"McKenna","sequence":"additional","affiliation":[{"name":"13Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Kyoung","family":"Ryu Tiger","sequence":"additional","affiliation":[{"name":"13Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4272-9214","authenticated-orcid":false,"given":"Megan","family":"Sears-Smith","sequence":"additional","affiliation":[{"name":"14Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[{"name":"14Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5108-6623","authenticated-orcid":false,"given":"Chelsea","family":"Peterson","sequence":"additional","affiliation":[{"name":"15Division of Hematology and Cellular Therapy, Allegheny Health Network, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Khan","sequence":"additional","affiliation":[{"name":"15Division of Hematology and Cellular Therapy, Allegheny Health Network, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4556-5713","authenticated-orcid":false,"given":"Sean P.","family":"Bliven","sequence":"additional","affiliation":[{"name":"16Division of Hematology and Oncology, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Narkhede","sequence":"additional","affiliation":[{"name":"16Division of Hematology and Oncology, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Gibson","sequence":"additional","affiliation":[{"name":"17Section of Hematology\/Oncology, University of Chicago Comprehensive Cancer Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kline","sequence":"additional","affiliation":[{"name":"17Section of Hematology\/Oncology, University of Chicago Comprehensive Cancer Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Munoz","sequence":"additional","affiliation":[{"name":"18Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3613-521X","authenticated-orcid":false,"given":"Rodolfo","family":"Garza-Morales","sequence":"additional","affiliation":[{"name":"18Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4437-9377","authenticated-orcid":false,"given":"Carrie I.","family":"Ho","sequence":"additional","affiliation":[{"name":"19Division of Hematology and Oncology, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5354-7593","authenticated-orcid":false,"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[{"name":"19Division of Hematology and Oncology, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9763-0137","authenticated-orcid":false,"given":"Alex","family":"Niu","sequence":"additional","affiliation":[{"name":"20Division of Hematology, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Hernandez-Ilizaliturri","sequence":"additional","affiliation":[{"name":"20Division of Hematology, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadzai","family":"Chinyengetere","sequence":"additional","affiliation":[{"name":"21Department of Medicine, Duke University, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Dave","sequence":"additional","affiliation":[{"name":"21Department of Medicine, Duke University, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayef","family":"Abdel-Razeq","sequence":"additional","affiliation":[{"name":"22Hematology Oncology Division, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-1219","authenticated-orcid":false,"given":"Muhamad Alhaj","family":"Moustafa","sequence":"additional","affiliation":[{"name":"22Hematology Oncology Division, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo F.","family":"Caimi","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2025103011210978900_bib1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1200\/JCO.20.01751","article-title":"Autologous stem cell transplantation in the management of relapsed non-Hodgkin lymphoma","volume":"39","author":"Alencar","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025103011210978900_bib2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2217\/fon-2018-0788","article-title":"Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA","volume":"15","author":"Morrison","year":"2019","journal-title":"Future Oncol"},{"issue":"10","key":"2025103011210978900_bib3","first-page":"1001.e1","article-title":"Autologous stem cell transplant in fit patients with late relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy","volume":"30","author":"Tun","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"9","key":"2025103011210978900_bib4","first-page":"610","article-title":"Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma","volume":"28","author":"Tun","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"5","key":"2025103011210978900_bib5","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/jha2.970","article-title":"Real-world outcomes of patients with relapsed\/refractory large B-cell lymphoma receiving second-line therapy in England","volume":"5","author":"Fox","year":"2024","journal-title":"EJHaem"},{"issue":"5","key":"2025103011210978900_bib6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2025103011210978900_bib7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"2025103011210978900_bib8","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"14","key":"2025103011210978900_bib9","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"30","key":"2025103011210978900_bib10","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1200\/JCO.23.02786","article-title":"Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"42","author":"Jain","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025103011210978900_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025103011210978900_bib12","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025103011210978900_bib13","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025103011210978900_bib14","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"issue":"9","key":"2025103011210978900_bib15","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2025103011210978900_bib16","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"issue":"12","key":"2025103011210978900_bib17","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3\u00d7CD20 bispecific T-cell-engaging antibody relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"2025103011210978900_bib18","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"2025103011210978900_bib19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"27","key":"2025103011210978900_bib20","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"23","key":"2025103011210978900_bib21","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1182\/bloodadvances.2023011384","article-title":"TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era","volume":"7","author":"Landsburg","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2025103011210978900_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"2025103011210978900_bib23","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1002\/hem3.62","article-title":"Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy","volume":"8","author":"Iacoboni","year":"2024","journal-title":"Hemasphere"},{"issue":"1","key":"2025103011210978900_bib24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-024-01608-8","article-title":"Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment","volume":"17","author":"Iacobon","year":"2024","journal-title":"J Hematol Oncol"},{"key":"2025103011210978900_bib25","doi-asserted-by":"crossref","first-page":"611366","DOI":"10.3389\/fimmu.2021.611366","article-title":"Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment","volume":"12","author":"Yan","year":"2021","journal-title":"Front Immunol"},{"issue":"suppl 1","key":"2025103011210978900_bib26","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2024-211076","article-title":"Risk factors for cytokine release syndrome in patients receiving bispecific antibodies for B-cell lymphoma: a single-center, retrospective cohort study [abstract]","volume":"144","author":"Yang","year":"2024","journal-title":"Blood"},{"issue":"14","key":"2025103011210978900_bib27","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/bloodadvances.2023011089","article-title":"Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma","volume":"8","author":"Gritti","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2025103011210978900_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/bjh.19503","article-title":"Relapse after glofitamab, a novel unmet medical need with high rates of CD20 loss","volume":"205","author":"Carlo-Stella","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"2025103011210978900_bib29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bjh.19455","article-title":"Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high","volume":"205","author":"Grigg","year":"2024","journal-title":"Br J Haematol"},{"issue":"9","key":"2025103011210978900_bib30","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2023022348","article-title":"Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas","volume":"143","author":"Schuster","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2025103011210978900_bib31","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"12","key":"2025103011210978900_bib32","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"issue":"27","key":"2025103011210978900_bib33","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"26","key":"2025103011210978900_bib34","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood.2023021274","article-title":"Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study","volume":"142","author":"Qualls","year":"2023","journal-title":"Blood"},{"issue":"24","key":"2025103011210978900_bib35","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025103011210978900_bib36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Alarcon Tomas","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"2025103011210978900_bib37","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/hon.3174","article-title":"Glofitamab in relapsed\/refractory diffuse large B-cell lymphoma: real-world data","volume":"41","author":"Birtas Atesoglu","year":"2023","journal-title":"Hematol Oncol"},{"issue":"15","key":"2025103011210978900_bib38","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/bloodadvances.2024014903","article-title":"Safety and efficacy of glofitamab for relapsed\/refractory large B-cell lymphoma in a multinational real-world study","volume":"9","author":"Shumilov","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"2025103011210978900_bib39","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/cncr.35217","article-title":"Glofitamab as a salvage treatment for B-cell lymphomas in the real world: a multicenter study in Taiwan","volume":"130","author":"Hsu","year":"2024","journal-title":"Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/18\/2177\/2418424\/blood_bld-2025-029117-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/18\/2177\/2418424\/blood_bld-2025-029117-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T15:21:23Z","timestamp":1761837683000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/18\/2177\/546196\/Real-world-outcomes-of-patients-with-aggressive-B"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":39,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,10,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029117","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,30]]},"published":{"date-parts":[[2025,10,30]]}}}